NCT02910063 2021-01-13Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHLAmgenPhase 2/3 Completed41 enrolled 18 charts
NCT00147121 2016-09-22Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)Japan Clinical Oncology GroupPhase 2/3 Completed300 enrolled